Medtronic (MDT) announced “MiniMed” as the name for the planned new diabetes company following the intended separation. The name honors the company’s roots, reflecting its original name prior to its acquisition by Medtronic in 2001, and a deep 40-year history of being at the forefront of transforming diabetes care around the world. Medtronic is targeting completion of the planned separation within 18 months of the initial announcement, subject to customary conditions and legal requirements including consultations with works councils and other employee representative bodies.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Deutsche Bank Sounds Alarm on Intuitive Surgical Stock (ISRG) with a Rare ‘Sell’ Rating
- Medtronic’s Diabetes Division Spin-Off: Hold Rating Amid Modest Immediate Value Potential
- Largest borrow rate increases among liquid names
- Medtronic call volume above normal and directionally bullish
- Medtronic’s Hold Rating: Navigating Profit Decline, Innovation Challenges, and Market Threats
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue